Trehalose Analogues Covalent Binding Mycobacterium Tuberculosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing trehalose analogues for detecting and targeting Mycobacterium tuberculosis face issues with specificity due to non-covalent association with the bacterial cell wall and potential metabolism by other microorganisms, leading to reduced effectiveness.
Innovation Solution
Development of trehalose analogues with specific chemical modifications that allow covalent binding to the mycobacterial cell wall, utilizing bioorthogonal chemistry for detection and therapeutic delivery, and incorporating non-native lipids with truncated chains for improved solubility and specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If known trehalose analogues are used for detecting and targeting Mycobacterium tuberculosis, then they can associate with the bacterial cell wall, but they undergo non-covalent association which leads to shedding and loss of specificity
Solution Approach 1:
The patent modifies the chemical parameters of trehalose analogues by introducing non-native lipids with truncated chains and specific functional groups (alkynyl, azido, fluorinated groups) to enable covalent bonding. This changes the binding mechanism from non-covalent to covalent association, resolving the contradiction between reliability and stability.
Solution Approach 2:
The invention creates composite structures by combining trehalose core with modified lipid tails containing non-native functional groups. These composite molecules (trehalose analogues with non-native lipids) achieve both stable covalent binding to the cell wall and resistance to metabolism, simultaneously improving reliability and stability.
2Reliability
If known trehalose analogues are used for detecting and targeting Mycobacterium tuberculosis, then they can potentially be metabolized by microorganisms, but this metabolism by non-mycobacterial microorganisms reduces specificity
Solution Approach 1:
The patent changes the chemical parameters of the lipid portion of trehalose analogues by introducing non-native functional groups (alkynyl, azido, fluorinated groups) that are not recognized by microbial metabolic enzymes. This makes the analogues resistant to metabolism by non-mycobacterial microorganisms while maintaining recognition and uptake by mycobacteria, thereby improving specificity.
3Reliability
If trehalose analogues with non-native lipids are used, then solubility and specificity are improved, but the chemical structure becomes more complex
Solution Approach 1:
The patent segments the trehalose molecule into a core disaccharide portion and separate lipid tail portions. The lipid tails are independently modified with non-native functional groups, allowing systematic optimization of solubility and specificity without complicating the core trehalose structure. This segmentation enables modular design that improves reliability while managing complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified trehalose analogues demonstrate enhanced specificity and stability for Mycobacterium tuberculosis, reducing off-target effects and improving diagnostic and therapeutic outcomes by covalently binding to the bacterial cell wall and utilizing bioorthogonal chemistry for targeted delivery.
Implementation Method 1
known trehalose analogues can undergo lipidation and subsequent non-covalent association with the Mtb cell wall
Data Source
AI summary
Described herein are trehalose analogues. Also described herein are methods of making the trehalose analogues and uses of the analogues. For example, the disclosed trehalose analogues may be useful in the detection of bacteria.